Editas Medicine, Inc.EDITNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank25
3Y CAGR-38.6%
5Y CAGR-23.8%
Year-over-Year Change
Research and development spending
3Y CAGR
-38.6%/yr
vs +17.9%/yr prior
5Y CAGR
-23.8%/yr
Recent deceleration
Acceleration
-56.5pp
Decelerating
Percentile
P25
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $40.52M | -79.7% |
| 2024 | $199.25M | +12.2% |
| 2023 | $177.65M | +1.5% |
| 2022 | $174.96M | +22.8% |
| 2021 | $142.51M | -9.8% |
| 2020 | $158.00M | +63.1% |
| 2019 | $96.90M | +6.9% |
| 2018 | $90.65M | +9.0% |
| 2017 | $83.16M | +45.9% |
| 2016 | $56.98M | - |